Regarding the new coronavirus vaccine developed by American pharmaceutical giant Pfizer, a clinical trial conducted on Japanese people in Japan also confirmed an increase in "neutralizing antibodies" that suppress the action of the virus as in overseas. I found out by interviewing.
The Ministry of Health, Labor and Welfare plans to hold an expert group on the 12th to decide whether or not to approve it.
Pfizer signed a contract with the Japanese government to supply vaccines for 72 million people by the end of the year, and last December applied for approval from the Ministry of Health, Labor and Welfare.
Pfizer said that 95% efficacy was confirmed in clinical trials conducted in more than 40,000 people overseas, and at the end of last month, it also submitted data on clinical trials conducted in 160 Japanese people over 20 years old in Japan. ..
The Ministry of Health, Labor and Welfare is examining whether there is a difference in efficacy and safety depending on the race, but in domestic clinical trials, the number of "neutralizing antibodies" that suppress the action of the virus is increasing in people who have been vaccinated as in overseas. It was found by interviewing the people concerned that it was confirmed.
The younger the person, the more neutralizing antibodies tended to increase.
On the 12th, the Ministry of Health, Labor and Welfare will hold a subcommittee made up of experts to ask for a decision on whether or not to approve the vaccination.
If the subcommittee approves, the Ministry of Health, Labor and Welfare will proceed with the procedure for formal approval.